Clinical Trial Update: Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing a fixed-dose combination tablet of saxagliptin 2.5 mg and metformin 850 mg with co-administered saxagliptin 2.5 mg and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Saxagliptin (saxagliptin)
• Saxagliptin/Metformin fixed-dose combination tablet
• metformin (metformin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2012-02-08